

Product Name: TGX-221 Revision Date: 01/10/2021 Product Data Sheet

VH

TGX-221

Cat. No.:	A2681
CAS No.:	<mark>6636</mark> 19-89-4
Formula:	C21H24N4O2
M.Wt:	364.44
Synonyms:	
Target:	PI3K/Akt/mTOR Signaling
Pathway:	PI3K
Storage:	Store at -20°C
	210

Solvent & Solubility

	insoluble in H2O; insoluble in EtOH; \geq 68.7 mg/mL in DMSO with gentle warming				
Preparing In Vitro Stock Solutions	Preparing	Mass Solvent Concentration	1mg	5mg	10mg
	1 mM	2.7439 mL	13.7197 mL	27.4394 mL	
	810	5 mM	0.5488 mL	2.7439 mL	5.4879 mL
	PErsonal	10 mM	0.2744 mL	1.3720 mL	2.7439 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

PI3Kβ inhibitor, potent, selective and ATP competitive

IC₅₀ & Target

In Vitro

0.005 μ M (PI3-kinase β), 0.1 μ M (PI3-kinase δ), 5 μ M (PI3-kinase δ), \geq 3.5 μ M (PI3-kinase γ)

Cell Via	bility	Assay
----------	--------	-------

PC3 cells
The solubility of this compound in DMSO is >68.7mg/mL. General tips for
obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes
and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
below -20°C for several months.
0.2, 2 and 20 μM; 24 ~ 72 hrs

1 | www.apexbt.com

	Applications:	In PC3 cells, TGX-221 treatment (0.2, 2, and 20 $\mu M)$ inhibited cell proliferation,	
		and significantly reduced the activity of the p110 β PI3K isoform.	
	Animal experiment		
In Vivo	Animal models:	FeCl3-induced arterial thrombosis in mice	
	Dosage form:	0.3 + 0.3, 1 + 1, 3 + 3 mg/kg + mg/kg/hr; i.v.	
	Applications:	At the doses of 1 + 1 (49 % ± 13.9%) and 3 + 3 (88 % ± 10.6%), TGX-221	
	PEr content	improved integrated blood flow over 30 mins in a mouse model. In addition, Tail	
	San	bleeding time (BT) (sec) increased with TGX-221 doses of 3 + 3 (median 1560)	
		and 1 + 1 (1305). In all TGX-221 groups, mean renal BT (sec) also increased.	
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may	
		slightly differ with the theoretical value. This is caused by an experimental	
		system error and it is normal.	

Product Citations



See more customer validations on www.apexbt.com.

References

[1]. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Gr?nning LM, Chong ML, Anagnostou SH, Jackson SP, Daniele N, Shepherd PR. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J. 2007 Jun 15;404(3):449-58.

[2]. Straub A, Wendel HP, Dietz K, Schiebold D, Peter K, Schoenwaelder SM, Ziemer G. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation. Thromb Haemost. 2008 Mar;99(3):609-15.

[3]. Bird JE, Smith PL, Bostwick JS, Shipkova P, Schumacher WA. Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice. Thromb Res. 2011 Jun;127(6):560-4.

Caution



FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.













